MIAMI, FL--(MARKET WIRE)--Jul 2, 2007 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News) (“DOR” or the “Company”) announced today that the first results from testing of a multivalent form of its botulinum toxin vaccine, BT-VACC(TM), have been published in the journal Infection and Immunity (Ravichandran et al., 2007, Infection and Immunity, v. 75, p. 3043 ). These results are the first that describe the protective immunity elicited by a multivalent vaccine that is active by the mucosal route. The vaccine consists of a combination of three non-toxic subunits of botulinum toxin that induced protection against the corresponding versions of the natural toxins.
